UBS Group AG Sells 51,663 Shares of Tarsus Pharmaceuticals, Inc. $TARS

UBS Group AG lessened its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 43.6% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 66,899 shares of the company’s stock after selling 51,663 shares during the period. UBS Group AG’s holdings in Tarsus Pharmaceuticals were worth $5,478,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Deep Track Capital LP boosted its position in Tarsus Pharmaceuticals by 71.4% during the third quarter. Deep Track Capital LP now owns 3,000,000 shares of the company’s stock valued at $178,290,000 after acquiring an additional 1,250,000 shares during the last quarter. M&T Bank Corp raised its position in shares of Tarsus Pharmaceuticals by 11,730.0% in the 4th quarter. M&T Bank Corp now owns 437,119 shares of the company’s stock worth $35,791,000 after acquiring an additional 433,424 shares in the last quarter. MPM Bioimpact LLC bought a new position in shares of Tarsus Pharmaceuticals in the 2nd quarter worth about $13,834,000. TimesSquare Capital Management LLC acquired a new position in shares of Tarsus Pharmaceuticals in the 3rd quarter valued at about $15,898,000. Finally, Qube Research & Technologies Ltd lifted its stake in shares of Tarsus Pharmaceuticals by 86.1% in the 2nd quarter. Qube Research & Technologies Ltd now owns 459,436 shares of the company’s stock valued at $18,612,000 after purchasing an additional 212,592 shares during the period. Institutional investors and hedge funds own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Price Performance

TARS stock opened at $64.79 on Thursday. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.74 and a quick ratio of 3.71. The company’s 50-day moving average is $66.42 and its 200-day moving average is $71.48. The stock has a market capitalization of $2.79 billion, a PE ratio of -56.83 and a beta of 0.52. Tarsus Pharmaceuticals, Inc. has a 1 year low of $38.51 and a 1 year high of $85.25.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its earnings results on Wednesday, May 6th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.24. Tarsus Pharmaceuticals had a negative return on equity of 14.19% and a negative net margin of 9.02%.The business had revenue of $162.05 million during the quarter, compared to analyst estimates of $149.60 million. Equities research analysts expect that Tarsus Pharmaceuticals, Inc. will post -0.71 EPS for the current fiscal year.

Insider Transactions at Tarsus Pharmaceuticals

In other news, General Counsel Bryan Wahl sold 4,231 shares of the business’s stock in a transaction that occurred on Thursday, March 19th. The stock was sold at an average price of $67.00, for a total transaction of $283,477.00. Following the completion of the sale, the general counsel owned 63,959 shares in the company, valued at $4,285,253. The trade was a 6.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Elizabeth Yeu Lin sold 390 shares of the company’s stock in a transaction that occurred on Thursday, March 19th. The stock was sold at an average price of $67.00, for a total value of $26,130.00. Following the transaction, the insider directly owned 23,308 shares in the company, valued at $1,561,636. The trade was a 1.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 79,391 shares of company stock valued at $5,432,035. Company insiders own 9.64% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on TARS. Guggenheim raised their target price on Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Oppenheimer began coverage on Tarsus Pharmaceuticals in a research note on Friday, April 24th. They issued an “outperform” rating and a $98.00 price target on the stock. Lifesci Capital upgraded Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Monday, March 16th. HC Wainwright reaffirmed a “buy” rating and set a $88.00 price objective on shares of Tarsus Pharmaceuticals in a research report on Monday, May 4th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Tuesday, April 21st. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $90.67.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.